As of the 12/31 financials, the company had $12.85k in cash(equivalents) and had enough to continue operations for several more months. Weeks after the filing, they announced the appointment of Freilich as a Sr. advisor for CONJUMAB-A trials as well as all their programs. I have to think that they should be updating via news or a filing on some type of financing soon.
My posts are solely my opinion unless presented with (or directed to) factual information. All investors are strongly encouraged by myself to do their own due diligence before making an investment decision.